Efficacy Prediction of Platelet Count Trajectories after Induction Therapy with Venetoclax Combined with Azacitidine in Newly Diagnosed AML Patients.
10.19746/j.cnki.issn.1009-2137.2025.02.004
- Author:
Qian-Ying MA
1
;
Xiao-Rui JING
1
;
Han-Chun WANG
1
;
Hui-Rong WU
1
;
Juan CHENG
1
Author Information
1. The First Clinical College of Lanzhou University,Lanzhou 730000, Gansu Province, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
venetoclax;
azacitidine;
platelet;
group-based trajectory modeling
- MeSH:
Humans;
Leukemia, Myeloid, Acute/blood*;
Sulfonamides/administration & dosage*;
Azacitidine/therapeutic use*;
Platelet Count;
Retrospective Studies;
Bridged Bicyclo Compounds, Heterocyclic/administration & dosage*;
Male;
Female;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Induction Chemotherapy;
Survival Rate
- From:
Journal of Experimental Hematology
2025;33(2):331-338
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate platelet count trajectories after induction therapy with venetoclax combined with azacitidine (VA regimen) in newly diagnosed AML patients and further analyze its clinical significance.
METHODS:Clinical date of 50 newly diagnosed AML patients who received VA treatment from March 2020 to July 2023 in Department of Hematology of the First Hospital of Lanzhou University were retrospectively collected. The platelet trajectories after induction chemotherapy were constructed by using group-based trajectory modeling. To study the association between diverse trajectories of platelet counts and compound complete remission (cCR) rate, overall response rate (ORR), minimal residual disease (MRD) negative rate and overall survival (OS) rate. The Cox proportional hazard model was used to evaluate the relationship between platelet trajectory and OS. The logistic regression was used to analyze the influence of individual characteristics on platelet trajectory.
RESULTS:Two platelet trajectories were identified based on the model, including platelet slowly increased group (n=31, 62.0%) and platelet rapidly increased group (n=19, 38.0%). There were statistically significant differences in cCR rate, ORR and OS rate between platelet slowly increased group and platelet rapidly increased group (all P < 0.05). The Cox regression analysis showed that platelet rapidly increased group was associated with a decreased risk of mortality compared with platelet slowly increased group (HR=0.153, 95%CI : 0.045-0.527, P =0.003). Logistic regression analysis showed that IDH1/2 mutation (OR =3.908, 95%CI : 1.023-14.923, P =0.046) and platelet transfusion (OR =0.771, 95%CI : 0.620-0.959, P =0.020) were independent influencing factors of platelet trajectory.
CONCLUSION:The dynamic trajectory of platelet counts in newly diagnosed AML patients who received VA treatment can serve as a significant indicator to observe the efficacy and prognosis. The platelet rapidly increased is an independent protective factor for good prognosis. TheIDH1 /2 mutation and platelet transfusion are independent influencing factors of platelet trajectory.
